Patients treated with mogamulizumab showed a trend toward improved OS compared to those not receiving mogamulizumab across risk-stratified groups according to the new Cutaneous Lymphoma International ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback